ARID1A-induced transcriptional reprogramming rewires signalling responses to drug treatment in melanoma
Charlie George Barker, Sumana Sharma, Ana Mafalda Santos…·Evangelia Petsalaki
This study reveals how ARID1A-mediated transcriptional rewiring drives resistance to MAPK inhibitors in melanoma by altering signalling pathways, immune interactions, and receptor dynamics, highlighting potential targets for combinatorial therapies.